The Price of Global Health: Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation

Front Cover
Ashgate Publishing Limited, Mar 1, 2011 - Law - 374 pages
Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How do drug companies set prices and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can an industry that produces life saving drugs have a poorer public reputation than gun and tobacco industries that produce products that kill? Ed Schoonveld, a leading expert and consultant in global pharmaceutical pricing and market access issues, explains how pharmaceutical prices are determined in a complex global player environment and what factors influence the process. His insights will help a wide range of audiences from healthcare industry professionals to policy makers and the broader public to gain a better understanding of this highly complex and emotionally charged field. The Price of Global Health is the first book of its kind: an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much needed and invaluable resource for anybody interested, involved in or affected by the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development; including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs.

What people are saying - Write a review

We haven't found any reviews in the usual places.

Other editions - View all

About the author (2011)

Ed Schoonveld is one of the leading experts in Global Pharmaceutical Pricing and Market Access. He has unparalleled experience as head of Global Market Access and Pricing functions in Wyeth, Lilly and BMS, as well as a consulting leader in Cambridge/IMS and a number of other organizations. Currently he is helping drug industry clients structure strategic solutions as Principal and Practice Lead for the Market Access and Pricing research and consulting practice at ZS Associates.

Bibliographic information